Lessons Learned from Clinical and Basic Research Applied to the Study of Patients with Severe Insulin Resistance

  • David E. Moller
  • Heike Benecke
Part of the Contemporary Biomedicine book series (CB, volume 15)


Insulin resistance is a prevalent physiological defect implicated in the pathogenesis of a variety of disorders, including noninsulin-dependent diabetes mellitus (NIDDM), obesity, hypertension, polycystic ovary syndrome (PCOS), and atherosclerosis. For the large majority of patients, the molecular basis for insulin resistance still remains poorly understood. This chapter will focus on defining correlations between observations that have been made when either basic or clinical research approaches were applied to the study of patients with severe insulin resistance. The topic of insulin receptor mutations will be discussed, especially the extent to which clinical research has helped us to understand mechanisms by which insulin receptor mutations lead to insulin resistance. Given that not all patients with severe insulin resistance have mutations involving the insulin receptor gene, we will also discuss aspects of basic and clinical research that have a bearing on other potential pathophysiologic mechanisms. The implications of studies of subjects with severe insulin resistance for the pathogenesis of insulin resistance associated with obesity, NIDDM, and other common disorders will also be explored.


Insulin Resistance Insulin Receptor Insulin Binding Acanthosis Nigricans Severe Insulin Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kahn CR, Flier JS, Bar RS, Archer JA, Gorden P, Martin NM, Roth J. The syndromes of insulin resistance and acanthosis nigricans: insulin receptor disorders in man. New Engl J Med 1976; 294: 739–745.PubMedCrossRefGoogle Scholar
  2. 2.
    Lerne CE, Wajchenberg BL, Lerario AC, Goldman J, Borges JL. Acanthosis nigricans, hirsutism, insulin resistance and insulin receptor defect. Clin Endocrinol 1982; 17: 43–49.CrossRefGoogle Scholar
  3. 3.
    Flier JS, Eastman RC, Minaker KL, Matteson D, Rowe JW. Acanthosis nigricans in obese women with hyperandrogenism: characterization of an insulin-resistant state distinct from the type A and B syndromes. Diabetes 1985; 34: 101–107.PubMedCrossRefGoogle Scholar
  4. 4.
    Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. New Engl J Med 1991; 325: 938–948.PubMedCrossRefGoogle Scholar
  5. 5.
    Moller DE, O’Rahilly S. Congenital syndromes of severe insulin resistance. In: Insulin Resistance. Moller DE, ed. Chichester: John Wiley, 1993; pp. 49–81.Google Scholar
  6. 6.
    Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance, and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983; 147: 90–101.PubMedGoogle Scholar
  7. 7.
    Dunaif A, Hoffman AR, Scully RE, Flier JS, Longcope C, Levy LT, Crowley WF. Clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans. Obstet Gynecol 1985; 66: 545–552.Google Scholar
  8. 8.
    Flier JS, Young JB, Landsberg L. Familial insulin resistance with acanthosis nigricans, acral hypertropy and muscle cramps: a new syndrome. New Engl J Med 1980; 390: 970–973.CrossRefGoogle Scholar
  9. 9.
    Moller DE, Cohen O, Yamaguchi Y, Azziz R, Eberle A, Flier JS. Prevalence of mutations in the insulin receptor gene in subjects with features of the Type A syndrome of insulin resistance. Diabetes 1994; 43: 247–255.PubMedCrossRefGoogle Scholar
  10. 10.
    Moller DE, Yokota A, White MF, Pazianos AG, Flier JS. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem 1990; 265: 14, 979–14, 985.Google Scholar
  11. 11.
    Nakamura F, Taira M, Hashmoto N, Makino H, Sasaki N. Familial type C syndrome of insulin resistance and short stature with possible autosomal dominant transmission. Endocrinol Jpn 1989; 36: 349–358.PubMedCrossRefGoogle Scholar
  12. 12.
    Holdaway IM, Frengley PA, Graham FM, Wong M. Insulin resistance with acanthosis nigricans and acral hypertrophy. NZ Med J 1984; 97: 286–288.Google Scholar
  13. 13.
    Low L, Chernausek SD, Sperling MA. Acromegaloid patients with type A insulin resistance: parallel defects in insulin and insulin-like growth factor-I receptors and biological responses in cultured fibroblasts. J Clin Endocrinol Metab 1989; 69: 329–337.PubMedCrossRefGoogle Scholar
  14. 14.
    Fox R, Wardlie PG, Clarke L, Hull MG. Acromegaloid bone changes in severe polycystic ovarian disease: an effect of hyperinsulinemia? Case report. Br J Obstet Gynaecol 1991; 98: 410–412.PubMedCrossRefGoogle Scholar
  15. 15.
    Flier JS, Moller DE, Moses AC, O’Rahilly S, Chaiken R, Grigorescu F, Kahn BB, Elahi D, Weinreb JE, Eastman R. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993; 76: 1533–1541.PubMedCrossRefGoogle Scholar
  16. 16.
    Schwenk WF, Rizza RA, Mandarino LJ, Gerich JE, Hayles AB, Haymond MW. Familial insulin resistance and acanthosis nigricans. Presence of a postbinding defect. Diabetes 1986; 35: 33–37.PubMedCrossRefGoogle Scholar
  17. 17.
    Scarlett JA, Kolterman OG, Moore P, Saekow M, Insel J, Griffin J, Mako M, Rubenstein AH, Olefsky JM. Insulin resistance and diabetes due to a genetic defect in insulin receptors. J Clin Endocrinol Metab 1982; 55: 123–131.PubMedCrossRefGoogle Scholar
  18. 18.
    Rudiger HW, Drery M, Kuhnau J, Bartelheimer H. Familial insulin-resistant diabetes secondary to an affinity defect of the insulin receptor. Hum Genet 1983; 64: 407–411.PubMedCrossRefGoogle Scholar
  19. 19.
    Cohen P, Harel C, Bergman R, Daoud D, Pam Z, Barzilai N, Armoni M, Karnieli E. Insulin resistance and acanthosis nigricans: evidence for a postbinding defect in vivo. Metabolism 1990; 39: 1006–1011.PubMedCrossRefGoogle Scholar
  20. 20.
    Grigorescu F, Herzberg V, King G, Meistas M, Elders J, Frazer T, Kahn CR. Defects in insulin binding and autophosphorylation of erythrocyte insulin receptors in patients with syndromes of severe insulin resistance and their parents. J Clin Endocrinol Metab 1987; 64: 549–556.PubMedCrossRefGoogle Scholar
  21. 21.
    Grigorescu F, Flier JS, Kahn CR. Characterization of binding and phosphorylation defects of insulin receptors in the Type A syndrome of insulin resistance. Diabetes 1986; 35: 127–138.PubMedCrossRefGoogle Scholar
  22. 22.
    Misbin RI, Green A, Alvarez IM, Almira EC, Dohm GL, Caro JF. Inhibition of insulin-stimulated glucose transport by factor extracted from serum of insulin-resistant patient. Diabetes 1988; 37: 1217–1225.PubMedCrossRefGoogle Scholar
  23. 23.
    Harrison LC, Dean B, Peluso I, Clark S, Ward G. Insulin resistance, acanthosis nigricans, and polycystic ovaries associated with a circulating inhibitor of postbinding insulin action. J Clin Endocrinol Metab 1985; 60: 1047–1052.PubMedCrossRefGoogle Scholar
  24. 24.
    Maddux BA, Sbraccia P, Reaven GM, Moller DE, Goldfine ID. Inhibitors of insulin receptor tyrosine kinase in fibroblasts from diverse patients with impaired insulin action: evidence for a novel mechanism for postreceptor insulin resistance. J Clin Endocrinol Metab 1993; 77: 73–79.PubMedCrossRefGoogle Scholar
  25. 25.
    Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart TA, Reaven GM, Goldine ID. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995; 373: 448–451.PubMedCrossRefGoogle Scholar
  26. 26.
    Flier JS, Kahn CR, Roth J. Receptors, antireceptor antibodies and mechanisms of insulin resistance. New Engl J Med 1979; 300: 413–419.PubMedCrossRefGoogle Scholar
  27. 27.
    Donohue WL, Uchida I. Leprechaunism: a euphemism for a rare familial disorder. J Pediatr 1954; 45: 505.PubMedCrossRefGoogle Scholar
  28. 28.
    Elsas LJ, Endo F, Preist JH, Strumlauf E. Leprechaunism: an inherited defect in insulin-receptor interaction. In: Congenital Metabolic Disease: Diagnosis and Treatment. Wapnir RA, ed. New York: Marcel Dekker, pp. 301–334, 1985.Google Scholar
  29. 29.
    Mendenhall EN. Tumor of the pineal body with high insulin resistance. J Indiana Med Assoc 1950; 43: 32–36.Google Scholar
  30. 30.
    Rabson SM, Mendenhall EN. Familial hypertrophy of pineal body, hyperplasia of adrenal cortex and diabetes mellitus: report of 3 cases. Am J Clin Pathol 1956; 26: 283–290.PubMedGoogle Scholar
  31. 31.
    West RJ, Lloyd JK, Turner WML. Familial insulin-resistant diabetes, multiple somatic anomalies, and pineal hyperplasia. Arch Dis Child 1975; 50: 703–708.PubMedCrossRefGoogle Scholar
  32. 32.
    West RJ, Leonard JV. Familial insulin resistance with pineal hyperplasia: metabolic studies and effect of hypophysectomy. Arch Dis Child 1980; 55: 619–621.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaplowitz PB, D’Ercole AJ. Fibroblasts from a patient with leprechaunism are resistant to insulin, epidermal growth factor, and somatomedin C. J Clin Endocrinol Metab 1982; 55: 741–748.PubMedCrossRefGoogle Scholar
  34. 34.
    Goodman PA, Sbraccia P, Brunetti A, Wong KY, Carter JD, Rosenthal SM, Goldfine ID. Growth factor receptor regulation in the Minn-1 leprechaun: defects in both insulin receptor and epidermal growth factor receptor gene expression. Metabolism 1992; 41: 504–509.PubMedCrossRefGoogle Scholar
  35. 35.
    Reddy SS, Kahn CR. Epidermal growth factor receptor defects in leprechaunism. A multiple growth factor-resistant syndrome. J Clin Invest 1989; 84: 1569–1576.PubMedCrossRefGoogle Scholar
  36. 36.
    Longo N, Griffin LD, Shuster RC, Langley S, Elsas LJ. Increased glucose transport by human fibroblasts with a heritable defect in insulin binding. Metabolism 1989; 38: 690–6697.PubMedCrossRefGoogle Scholar
  37. 37.
    Senior B, Gellis SS. The syndromes of total and partial lipodystrophy. Pediatrics 1964; 33: 593.PubMedGoogle Scholar
  38. 38.
    Rossini AA. Lipoatrophic diabetes. In: Joslin’s Diabetes Mellitus. Marble A, Krall LP, Bradley RF, Christlieb AR, Soeldner JS, ed. Philadelphia: Lea and Febiger, pp. 834–842, 1985.Google Scholar
  39. 39.
    Kobberling J. Genetic syndromes associated with lipoatrophic diabetes. In: The Genetics of Diabetes Mellitus. Creutzfeldt J, Kobberling J, Neel JV, ed. New York: Springer Verlag, pp. 147–154, 1976.Google Scholar
  40. 40.
    Oseid S, Studies in congenital generalized lipodystrophy (Seip-Berardinelli syndrome). I. Development of diabetes. Acta Endocrinol 1973; 72: 475–494.PubMedGoogle Scholar
  41. 41.
    Seip M, Trygstad O. Generalized lipodystrophy. Arch Dis Chil 1963; 38: 447.CrossRefGoogle Scholar
  42. 42.
    Dunningan MG, Cochrane M, Kelly A, Scott JW. Familial lipoatrophic diabetes with dominant transmission. Q JMed 1974; 49: 33–48.Google Scholar
  43. 43.
    Kobberling J, Willms B, Kattermann R, Creutzfeldt W. Lipodystrophy of the extremities. A dominantly inherited syndrome associated with lipoatrophic diabetes. Humangenetik 1975; 29: 111–120.PubMedCrossRefGoogle Scholar
  44. 44.
    Berg SW, Jersild RA, Powell RC. Studies of lipid synthesis and release. J Lab Clin Med 1970; 76: 1005, 1006.Google Scholar
  45. 45.
    Farber E, Vawler E. Clinico-pathological conference. J Pediatr 1964; 64: 138–143.CrossRefGoogle Scholar
  46. 46.
    Garg A, Fleckenstein JL, Peshock RM, Grundy SM. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 1992; 75: 358–361.PubMedCrossRefGoogle Scholar
  47. 47.
    Boucher BJ, Cohen RD, France MW, Mason SA. Plasma free fatty acid turnover in total lipodystrophy. Clin Endocrino11973; 4: 83–88.Google Scholar
  48. 48.
    Brunzell JD, Porte D Jr, Bierman EL. On the mechanisms of lipoatrophy in congenital lipodystrophy. Clin Res 1969; 17: 122.Google Scholar
  49. 49.
    Beylot M, Sautot G, Laville M, Cohen R. Metabolic studies on lipoatrophic diabetes: mechanism of hyperglycemia and evidence of resistance to insulin of lipid metabolism. Diabete Metab 1988; 14: 20–24.PubMedGoogle Scholar
  50. 50.
    Davidson MB, Young RT. Metabolic studies in partial lipodystrophy of the lower trunk and extremities. Diabetologia 1975; 11: 561–568.PubMedCrossRefGoogle Scholar
  51. 51.
    Cutler DL, Kaufmann S, Freidenberg GR. Insulin-resistant diabetes mellitus and hypermetabolism in mandibuloacral dysplasia: a newly recognized form of partial lipodystrophy. J Clin Endocrinol Metab 1991; 73: 1056–1061.PubMedCrossRefGoogle Scholar
  52. 52.
    Lawrence RD. Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances. A case throwing new light on the action of insulin. Lancet 1946; 1: 724.PubMedCrossRefGoogle Scholar
  53. 53.
    Sissons JGP, West RJ, Fallows J. The complement abnormalities of lipodystrophy. New Engl J Med 1976; 294: 461.PubMedCrossRefGoogle Scholar
  54. 54.
    White MF, Kahn CR. The insulin signaling system. J Biol Chem 1994; 269: 1–4.PubMedGoogle Scholar
  55. 55.
    Rosen OM. Structure and function of insulin receptors. Diabetes 1989; 38: 1508–1511.PubMedCrossRefGoogle Scholar
  56. 56.
    Taylor SI, Moller DE. Mutations of the insulin receptor gene. In: Insulin Resistance. Moller DE, ed. Chichester: John Wiley, pp. 83–111, 1993.Google Scholar
  57. 57.
    Taylor SI. Lilly lecture: molecular mechanisms of insulin resistance, lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992; 41: 1473–1490.PubMedCrossRefGoogle Scholar
  58. 58.
    Kadowaki T, Kadowaki H, Taylor SI. A nonsense mutation causing decreased levels of insulin receptor mRNA: detection by simplified technique for direct sequencing of genomic DNA amplified by the polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 658–662.PubMedCrossRefGoogle Scholar
  59. 59.
    Yoshimasa Y, Seino S, Whittaker J, Kakehi T, Kosaki A, Kuzuya H, Imura H, Bell GI, Steiner DF. Insulin resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 1988; 240: 784–787.PubMedCrossRefGoogle Scholar
  60. 60.
    Accili D, Mosthaf L, Ullrich A, Taylor SI. A mutation in the extracellular domain of the insulin receptor impairs the ability of insulin to stimulate receptor autophosphorylation. J Biol Chem 1991; 266: 434–439.PubMedGoogle Scholar
  61. 61.
    Chang P-Y, Benecke H, Le Marchand-Brustel Y, Lawitts J, Moller DE. Expression of a dominant-negative mutant human insulin receptor in the muscle of transgenic mice. J Biol Chem 1994; 269: 16, 034–16, 040.Google Scholar
  62. 62.
    Chang P-Y, Goodyear LJ, Benecke H, Markuns JS, Moller DE. Impaired insulin signaling in skeletal muscles from transgenic mice expressing kinase-deficient insulin receptors. J Biol Chem 1995; 270: 12, 593–12, 600.Google Scholar
  63. 63.
    Yamaguchi Y, Flier JS, Benecke H, Ransil BJ, Moller DE. Ligand binding properties of the two isoforms of the human insulin receptor. Endocrinology 1993; 132: 1132–1138.PubMedCrossRefGoogle Scholar
  64. 64.
    Krook A, Kimar S, Laing I, Boultan AJM, Wass JAH, O’Rahilly S. Molecular scanning of the insulin receptor gene in syndromes of insulin resistance. Diabetes 1994; 43: 357–368.PubMedCrossRefGoogle Scholar
  65. 65.
    Van der Vorm ER, Kuipers A, Bonenkamp JW, Meijer WJ, Van Maldergen L, Herwig J, Maassen JA. Patients with lipodystrophic diabetes express normal insulin receptors. Diabetologia 1993; 36: 172–174.PubMedCrossRefGoogle Scholar
  66. 66.
    Krook A, Brueton L, O’Rahilly S. Homozygous nonsense mutation in the insulin receptor gene in infant with leprechaunism. Lancet 1993; 342: 277, 278.Google Scholar
  67. 67.
    Dunaif A, Green G, Phelps RG, Lebwohl M, Futterweit W, Lewy L. Acanthosis nigricans, insulin action, and hyperandrogenism: clinical, histological, and biochemical findings. J Clin Endocrinol Metab 1991; 73: 590–595.PubMedCrossRefGoogle Scholar
  68. 68.
    Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989; 87: 269–272.PubMedCrossRefGoogle Scholar
  69. 69.
    Copeland KC, Nair KS, Kaplowitz PB, Robbins DC, Calles-Escandon J. Discordant metabolic actions of insulin in extreme lipodystrophy of childhood. J Clin Endocrinil Metab 1993; 77: 1240–1245.CrossRefGoogle Scholar
  70. 70.
    Cohen P, Barzilai N, Lerman A, Harel H, Szlman P, Kamieli E. Insulin effects on glucose and potassium metabolism in vivo: evidence for selective insulin resistance in humans. J Clin Endocrinol Metab 1991; 73: 564–568.PubMedCrossRefGoogle Scholar
  71. 71.
    Cruz PD, Hud JA. Excess insulin binding to insulin-like growth factor receptors: proposed mechanism for acanthosis nigricans. J Invest Dermatol 1992; 98: 82S - 85S.PubMedCrossRefGoogle Scholar
  72. 72.
    Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991; 12: 3–13.PubMedCrossRefGoogle Scholar
  73. 73.
    Morrow LA, O’Brien MB, Moller DE, Flier JS, Moses AC. Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome insulin resistance. J Clin Endocrinol Metab 1994; 79: 205–210.PubMedCrossRefGoogle Scholar
  74. 74.
    Kuzuya H, Matsuura N, Sakamoto M, et al. Trial of insulinlike growth factor 1 therapy for patients with extreme insulin resistance syndromes. Diabetes 1993; 42: 696–705.PubMedCrossRefGoogle Scholar
  75. 75.
    Flier JS, Minaker KL, Landsberg L, Young JB, Pallotta J, Rowe JW. Impaired in vivo insulin clearance in patients with severe target cell resistance of insulin. Diabetes 1982; 31: 132–135.PubMedCrossRefGoogle Scholar
  76. 76.
    Ferranini E, Muggeo M, Navalesi R, Pilo A. Impaired insulin degradation in a patient with insulin resistance and acanthosis nigricans. Am J Med 1982; 73: 148–154.CrossRefGoogle Scholar
  77. 77.
    Ciccarone A, Di Cianni G, Cionini R, Benzi L. In vitro and in vivo insulin metabolism in Type A syndrome of insulin resistance. Diabetes 1992; 41 (Suppl 1): 15A.Google Scholar
  78. 78.
    Cama A, Sierra ML, Ottini L, Kadowaki T, Gorden P. Imperato-McGinley J, Taylor SI. A mutation in the tyrosine kinase domain of the insulin receptor associated with insulin resistance in an obese woman. J Clin Endocrinol Metab 1991; 73: 894–901.PubMedCrossRefGoogle Scholar
  79. 79.
    Moller DE, Yokota A, Flier JS. Normal insulin receptor cDNA sequence in Pima Indians with non-insulin dependent diabetes mellitus. Diabetes 1989; 38: 1496–1500.PubMedCrossRefGoogle Scholar
  80. 80.
    O’Rahilly S, Choi WH, Patel P, Turner RC, Flier JS, Moller DE. Detection of mutations in the insulin receptor gene in non-insulin-dependent diabetic patients by analysis of single-stranded conformation polymorphisms. Diabetes 1991; 40: 777–782.PubMedCrossRefGoogle Scholar
  81. 81.
    Kan M, Kanai F, Iida M, Jinnouchi H, Todaka M, Imanaka T, Ito K, Nishioka Y, Ohnishi T, Kamohara S, Hayashi H, Murakami T, Kagawa S, Sano H, Hashimoto N, Yoshida S, Makino H, Ebina Y. Frequency of mutations of insulin receptor gene in Japanese patients with NIDDM. Diabetes 1995; 44: 1081–1086.PubMedCrossRefGoogle Scholar
  82. 82.
    Seely BL, Olefsky JM. Potential cellular and genetic mechanisms for insulin resistance in the common disorders of diabetes and obesity. In: Insulin Resistance. Moller DE, ed. Chichester: John Wiley, pp. 187–252, 1993.Google Scholar
  83. 83.
    Moller DE, Chang PY, Yaspelkis BB, Flier JS, Wallberg-Henriksson H, Ivy JL. Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose tolerance, and dyslipidemia. Endocrinology 1996; 137: 2397–2405.PubMedCrossRefGoogle Scholar
  84. 84.
    Taylor SI, Accili D, Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994; 43: 735–740.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • David E. Moller
  • Heike Benecke

There are no affiliations available

Personalised recommendations